Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DCTHNYSE:INFUNASDAQ:NPCENASDAQ:TMCI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCTHDelcath Systems$12.76-6.2%$14.71$7.17▼$18.23$473.64M0.87420,315 shs965,131 shsINFUInfuSystem$6.18-1.0%$5.71$4.61▼$9.97$129.88M1.81115,106 shs125,008 shsNPCENeuroPace$10.48-5.9%$12.84$5.45▼$18.98$365.38M1.93180,717 shs413,983 shsTMCITreace Medical Concepts$6.02+2.4%$6.29$4.54▼$10.79$369.79M0.69524,067 shs309,144 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCTHDelcath Systems+0.22%+2.56%-15.37%+8.19%+62.49%INFUInfuSystem+1.96%+0.97%+7.96%+16.42%-8.64%NPCENeuroPace+4.01%+5.39%-14.18%-15.03%+47.35%TMCITreace Medical Concepts+2.26%+2.44%+2.08%-27.85%-11.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDCTHDelcath Systems3.3218 of 5 stars3.55.00.00.01.62.50.6INFUInfuSystem2.4724 of 5 stars2.02.00.00.02.04.21.9NPCENeuroPace3.3682 of 5 stars3.43.00.00.02.44.20.6TMCITreace Medical Concepts2.4765 of 5 stars3.11.00.00.02.93.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCTHDelcath Systems 3.00Buy$24.0088.09% UpsideINFUInfuSystem 4.00Strong Buy$13.00110.36% UpsideNPCENeuroPace 2.83Moderate Buy$15.5047.90% UpsideTMCITreace Medical Concepts 2.29Hold$10.1668.72% UpsideCurrent Analyst Ratings BreakdownLatest INFU, TMCI, DCTH, and NPCE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025DCTHDelcath SystemsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.005/28/2025NPCENeuroPaceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.005/23/2025DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $29.005/14/2025NPCENeuroPaceJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $16.005/14/2025NPCENeuroPaceCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$17.00 ➝ $17.005/9/2025TMCITreace Medical ConceptsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.605/8/2025INFUInfuSystemB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/11/2025TMCITreace Medical ConceptsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$9.50 ➝ $8.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCTHDelcath Systems$37.21M11.94N/AN/A$2.15 per share5.93INFUInfuSystem$137.58M0.94$0.48 per share12.79$2.47 per share2.50NPCENeuroPace$79.91M4.30N/AN/A$0.27 per share38.81TMCITreace Medical Concepts$209.36M1.81N/AN/A$1.81 per share3.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCTHDelcath Systems-$26.39M-$0.50N/AN/AN/A-26.38%-29.44%-20.75%8/4/2025 (Estimated)INFUInfuSystem$870K$0.14103.0219.94N/A1.12%2.78%1.41%N/ANPCENeuroPace-$27.14M-$0.84N/AN/AN/A-29.42%-190.84%-25.08%8/12/2025 (Estimated)TMCITreace Medical Concepts-$55.74M-$0.85N/AN/AN/A-25.14%-48.69%-24.59%8/5/2025 (Estimated)Latest INFU, TMCI, DCTH, and NPCE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025NPCENeuroPace-$0.26-$0.21+$0.05-$0.21$21.85 million$22.52 million5/8/2025Q1 2025DCTHDelcath Systems$0.10$0.03-$0.07$0.03$16.83 million$19.80 million5/8/2025Q1 2025TMCITreace Medical Concepts-$0.31-$0.25+$0.06-$0.25$52.07 million$52.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDCTHDelcath SystemsN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/ANPCENeuroPaceN/AN/AN/AN/AN/ATMCITreace Medical ConceptsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCTHDelcath SystemsN/A15.9514.61INFUInfuSystem0.501.981.59NPCENeuroPace2.466.635.70TMCITreace Medical Concepts0.514.503.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCTHDelcath Systems61.12%INFUInfuSystem71.13%NPCENeuroPace78.83%TMCITreace Medical Concepts84.08%Insider OwnershipCompanyInsider OwnershipDCTHDelcath Systems17.94%INFUInfuSystem11.40%NPCENeuroPace20.50%TMCITreace Medical Concepts27.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDCTHDelcath Systems6034.83 million28.58 millionOptionableINFUInfuSystem41021.02 million19.10 millionOptionableNPCENeuroPace17032.80 million26.08 millionOptionableTMCITreace Medical Concepts25062.89 million45.46 millionOptionableINFU, TMCI, DCTH, and NPCE HeadlinesRecent News About These CompaniesLisanti Capital Growth LLC Makes New $2.12 Million Investment in Treace Medical Concepts, Inc. (NASDAQ:TMCI)June 29 at 6:33 AM | marketbeat.comTMCI Treace Medical Concepts, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) is favoured by institutional owners who hold 53% of the companyJune 21, 2025 | finance.yahoo.comAttention Long-Term Treace Medical Concepts, Inc. (™CI) Shareholders: Grabar Law Office is Investigating Claims on Your BehalfJune 13, 2025 | investing.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Given Consensus Recommendation of "Hold" by BrokeragesJune 12, 2025 | marketbeat.comKuehn Law Encourages Investors of Treace Medical Concepts, Inc. to Contact Law FirmJune 11, 2025 | prnewswire.comSecurities Lawsuit Alert: Treace Medical Concepts, Inc. (TMCI) Investors - Contact Levi & Korsinsky Before June 10, 2025June 10, 2025 | accessnewswire.comATreace Medical Concepts, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; June 10, 2025 Deadline to file Lead Plaintiff MotionJune 10, 2025 | globenewswire.comSecurities Class Action Lawsuit Filed Against Treace Medical Concepts, Inc. (TMCI) - Levi & Korsinsky Represents ShareholdersJune 10, 2025 | accessnewswire.comATMCI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Treace Medical Concepts, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 10, 2025 | globenewswire.comLost Money on Treace Medical Concepts, Inc. (TMCI)? Join Class Action Before June 10, 2025 - Contact Levi & KorsinskyJune 10, 2025 | accessnewswire.comAClass Action Filed Against Treace Medical Concepts, Inc. (TMCI) - June 10, 2025 Deadline to Join – Contact Levi & KorsinskyJune 10, 2025 | globenewswire.comTMCI DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important June 10 Deadline in Securities Class Action - TMCIJune 10, 2025 | accessnewswire.comAFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Treace MedicalJune 10, 2025 | businesswire.comDid You Lose Money on Treace Medical Concepts, Inc. (TMCI)? Levi & Korsinsky Urges Investors to Act Before June 10, 2025June 10, 2025 | accessnewswire.comAFINAL REMINDER TMCI DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Treace Medical Concepts, Inc. Investors to Participate in the Class Action LawsuitJune 10, 2025 | accessnewswire.comALevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 10, 2025 in Treace Medical Concepts, Inc. Lawsuit - TMCIJune 10, 2025 | prnewswire.comSquarepoint Ops LLC Has $137,000 Stock Position in Treace Medical Concepts, Inc. (NASDAQ:TMCI)June 10, 2025 | marketbeat.comShareholders of Treace Medical Concepts, Inc. (TMCI): Protect Your Rights Before June 10, 2025 - Contact Levi & KorsinskyJune 9, 2025 | accessnewswire.comATMCI FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action - TMCIJune 9, 2025 | accessnewswire.comATreace Medical Concepts, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – TMCIJune 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINFU, TMCI, DCTH, and NPCE Company DescriptionsDelcath Systems NASDAQ:DCTH$12.76 -0.84 (-6.18%) Closing price 04:00 PM EasternExtended Trading$12.80 +0.04 (+0.31%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.InfuSystem NYSE:INFU$6.18 -0.06 (-0.96%) Closing price 04:00 PM EasternExtended Trading$6.18 +0.00 (+0.08%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.NeuroPace NASDAQ:NPCE$10.48 -0.66 (-5.92%) Closing price 04:00 PM EasternExtended Trading$10.54 +0.06 (+0.56%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Treace Medical Concepts NASDAQ:TMCI$6.02 +0.14 (+2.38%) Closing price 04:00 PM EasternExtended Trading$6.07 +0.05 (+0.83%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
